genOway Société Anonyme engages in the development and sale of custom genetically-modified (GM) mouse models worldwide. The company provides technological solutions for transgenesis and mouse model design. It produces genetically modified models, including custom mouse models, such as knockout (KO) and knock in (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for use in vivo or in vitro studies. In addition, the company provides patented homologous recombination technology for the generation of humanized GM rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene at a time during the lifetime of the animal model. Further, it offers tetracycline on/off systems to control of gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and models that allow for inducible ablation of a given cell type, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Additionally, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology to bypass HPRT or Rosa26 loci. The company serves pharmaceutical and biotech companies, and academic institutes. genOway Société Anonyme was founded in 1999 and is headquartered in Lyon, France.
Type
Public
HQ
Lyon, FR
Employees
88 (est)

Genoway Locations

Lyon, FR

Genoway Metrics

Genoway Summary

Market capitalization

€10.3 M

Closing share price

€1.68

Genoway Market Value History

Genoway Company Life